An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)
Safety and Efficacy of Bb2121 (Ide-cel) Combinations in Patients with Multiple Myeloma (KarMMa-7)
Sponsor: Celgene Corporation
Enrolling: Male and Female Patients
IRB Number: AAAT3011
U.S. Govt. ID: NCT04855136
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if the investigational therapy, bb2121, in combination with other treatments, is safe and effective in treating relapsed and/or refractory multiple myeloma.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with multiple myeloma? Yes No
Are you able and willing to provide written informed consent? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE